PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29764490-3	2018	As hypoxia-inducible factor-1alpha (HIF-1alpha) is overexpressed in nasopharyngeal carcinoma (NPC) tissues, we performed the present study to evaluate the efficacy profile of evofosfamide in NPC.	TH 302	175-187	hypoxia inducible factor 1 subunit alpha	Homo sapiens	3-34	
29764490-3	2018	As hypoxia-inducible factor-1alpha (HIF-1alpha) is overexpressed in nasopharyngeal carcinoma (NPC) tissues, we performed the present study to evaluate the efficacy profile of evofosfamide in NPC.	TH 302	175-187	hypoxia inducible factor 1 subunit alpha	Homo sapiens	36-46	
29764490-9	2018	Histone H2AX phosphorylation (gammaH2AX) (a marker of DNA damage) expression increased while HIF-1alpha expression suppressed after evofosfamide treatment under hypoxic conditions.	TH 302	132-144	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-103	
27169385-11	2016	Hypoxia markers HIF-1alpha and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy.	TH 302	119-131	hypoxia inducible factor 1 subunit alpha	Homo sapiens	16-26	
26010414-9	2015	CONCLUSIONS: The combination of TH-302, VEGF-A inhibition, and RT is highly effective in preclinical models of sarcoma and is associated with increased DNA damage and apoptosis in endothelial cells and decreased HIF-1alpha activity.	TH 302	32-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	212-222